Document:

EX-4.5

 Exhibit 4.5 

FORM OF 2025 FIXED RATE GLOBAL NOTE 

[FACE OF 2025 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital UK plc 

3.125% Fixed Rate Senior Note due 2025 

Guaranteed on a Senior Basis by 

Haleon plc 
 CUSIP No.:
36264N AB0 
 ISIN: US36264NAB01 
  

					
		  		  	Principal Amount $
			
		  		  	 as revised by Schedule A

		  		  	 attached

		  		  	 hereto of Increases and

		  		  	 Decreases in this 2025

		  		  	 Fixed Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the
“Holder”) of $                     of 3.125% Fixed Rate Senior Notes due 2025 represented by this Global Note. GSK Consumer
Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales, promises to pay to the Holder, or registered assigns, the principal sum of
$                     as revised by the Schedule of Increases and Decreases in 2025 Fixed Rate Global Note attached hereto, on March 24,
2025. 
 In the event of a redemption or cancellation of the 2025 Fixed Rate Notes in part only, the 2025 Fixed Rate Notes evidenced by this
2025 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2025 Fixed Rate Notes represented by this 2025 Fixed Rate Global Note shall be the principal amount of 2025 Fixed Rate Notes most recently
entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

 Reference is hereby made to the further provisions of this 2025 Fixed Rate Note as set forth
on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	 GSK CONSUMER HEALTHCARE CAPITAL UK PLC

		
	 By:
	 	  

		 	Name:
		 	 Title:

  

					
	TRUSTEE’S CERTIFICATE OF AUTHENTICATION	  		  	
			
	Deutsche Bank Trust Company Americas,	  		  	
	as Trustee, certifies	  		  	
	that this is one of	  		  	
	the 2025 Fixed Rate Notes referred	  		  	
	to in the Indenture	  		  	

  

							
	By:	 	      
	 	Date:	 	                            
		 	 Authorized Signatory
	 		 	

  
 2 

 GUARANTEE 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY, England (the “Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Guarantee is endorsed and to the Trustee on behalf of each such Holder the due payment of all principal of and other amounts on, each Note payable by
GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales (the “UK Issuer”, which term includes any successor Person under the Indenture) under the Indenture. In case of the
failure of the UK Issuer, to punctually make any such payment or satisfy any such obligation in respect of the UK Issuer Notes, the Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the
same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the UK Issuer. 

The indebtedness evidenced by this Guarantee constitutes an unsubordinated and unsecured obligation of the Guarantor and ranks equally and
pari passu with all existing and future senior and unsecured obligations of the Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the
Guarantor. 
 The Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the UK Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Guarantor hereby waives diligence, presentment, demand
of payment, filing of claims with a court in the event of merger or bankruptcy of the UK Issuer, any right to require a proceeding first against the UK Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or with
respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional Amounts, if
any, payable in respect of such Note. This Guarantee is a guarantee of payment and not of collection. 
 The Guarantor shall be subrogated
to all rights of the Holder of such Note and the Trustee against the UK Issuer in respect of any amounts paid to such Holder by the Guarantor pursuant to the provisions of this Guarantee; provided, however, that the Guarantor shall not be
entitled to enforce, or to receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been
paid in full. 

  
 3 

 No reference herein to such Indenture and no provision of such Indenture shall alter or
impair the guarantees of the Guarantor, which are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Guarantee is endorsed. 

This Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been manually
or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Guarantee that are defined in such
Indenture shall have the meanings assigned to them in such Indenture. 
 This Guarantee shall be governed by and construed in accordance
with the laws of the State of New York. 

  
 4 

 IN WITNESS WHEREOF, the Guarantor has caused this Guarantee to be duly executed
this                    . 
  

			
	 HALEON PLC,
 as the
Guarantor

		
	By:	 	  

		 	Name:
		 	Title:
		
	By:	 	  

		 	Name:
		 	Title:

  
 5 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital UK plc 

3.125% Fixed Rate Senior Note due 2025 

Guaranteed on a Senior Basis by 

Haleon plc 
 Interest 

Interest on the 2025 Fixed Rate Notes will be payable at a rate of 3.125% per annum. 

Interest on the 2025 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing
on March 24, 2023 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2025 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed Rate
Notes Interest Payment Date. 
 The 2025 Fixed Rate Notes will accrue interest from (and including) September 24, 2022, or from the
most recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2025 Fixed Rate Notes will be paid on the basis of twelve
30-day months assuming a 360-day year. 
 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2025 Fixed Rate Notes and on the 2025 Fixed
Rate Notes Maturity Date, GSK Consumer Healthcare Capital UK plc (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of
payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender 2025 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2025 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the
transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by
the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its
discretion). 
 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the Guarantor
may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 

  
 6 

 Indenture 

The Issuer issued the 2025 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from
time to time in accordance with the terms thereof, the “Indenture”), among the Issuers, GSK plc, the Guarantor, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2025 Fixed Rate Notes
include those stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2025 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a
statement of those terms. Each Holder by accepting a 2025 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2025 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                aggregate principal amount. 
 The
2025 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Guarantor under the Guarantee, for the benefit of the Holders pursuant to the Indenture. 

Redemption 
 Unless earlier redeemed,
purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal amount on March 24, 2025. 

Optional Redemption for Tax Reasons  

The Issuer may redeem the 2025 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of
their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the 2025 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available
to the Issuer or the Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the Guarantor (or any Affiliate) and such withholding tax
obligation cannot be avoided by the use of reasonable measures available to the Issuer or the Guarantor (or any Affiliate); or 
 (b) the
Issuer determines, based upon an opinion of independent counsel of recognised standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United
Kingdom or the United States, which action is taken or brought on after the Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be
given earlier than 90 days prior to the earliest date on which the Issuer would be obligated to pay such Additional Amounts. 

  
 7 

 Make-Whole Redemption 

At any time prior to the 2025 Fixed Rate Notes Maturity Date, the Issuer may redeem the 2025 Fixed Rate Notes, in whole or in part, at their
option at any time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2025 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the
present values of the remaining scheduled payments of principal and interest on the 2025 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as to the redemption date) discounted to
the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, in each case plus
accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 
 Redemption upon a Change of Control Put Event

 If a Change of Control Put Event occurs with respect to the 2025 Fixed Rate Notes, the Holders will have the option to require the Issuer
to redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2025 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control
Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 Denominations; Transfer 

The 2025 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer 2025 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted
by the Indenture. 
 Persons Deemed Owners 

The registered Holder of this 2025 Fixed Rate Note may be treated as the owner of it for all purposes. 

Unclaimed Money 
 Any money deposited with
the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other amounts on, any 2025 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and
payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such 2025 Fixed Rate Note shall
thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with
respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

  
 8 

 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2025 Fixed Rate Notes or the Guarantee may be amended
with the consent of the Holders of a majority in principal amount of the 2025 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in
aggregate principal amount of the 2025 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any
Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide
for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2025 Fixed Rate Notes in addition to or in place of certificated
2025 Fixed Rate Notes. 
 Defaults and Remedies 

If certain Events of Default with respect to the 2025 Fixed Rate Notes shall occur, the principal amount of all the 2025 Fixed Rate Notes may
be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the 2025 Fixed Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the 2025 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 

Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may
become the owner or pledgee of 2025 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it
were not Trustee. 
 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2025 Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the Guarantor in this Indenture, or in any of the 2025 Fixed Rate Notes, or because of the creation of any indebtedness represented
thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the Guarantor) or the Guarantor or of any successor Persons thereof. Each Holder, by accepting
the 2025 Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2025 Fixed Rate Notes. Such waiver may not be effective to waive liabilities under U.S. federal
securities laws. 
 Authentication 

This 2025 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this 2025 Fixed Rate Note. 

  
 9 

 CUSIP Numbers 

The Issuer in issuing the 2025 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to
the accuracy of such numbers either as printed on the 2025 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2025 Fixed Rate Notes. The Issuer will promptly notify
the Trustee, in writing, of any change in the “CUSIP” number. 
 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and the Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the 2025 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and the Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Issuer and the Guarantor each have appointed GSK Consumer Healthcare Capital US LLC as its Authorized Agent upon
whom all writs, process and summonses may be served in any suit, action or proceeding arising out of or based upon the Indenture or the 2025 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To
the extent that either of the Issuer and the Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from
set-off or any legal process (whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the Guarantor have irrevocably waived and agreed not
to plead or claim such immunity in respect of their obligations under the Indenture or the 2025 Fixed Rate Notes. 
 The Issuer shall
furnish to any Holder upon written request and without charge to the Holder a copy of the Indenture which has in it the text of this 2025 Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital UK plc, attention: Mike Rowe (Group
Treasurer), e-mail: cf-treasury@haleon.com. 

  
 10 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2025 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2025 Fixed Rate Global Note have been made: 

 

									
	 Date of Exchange
	  	 Amount of decrease in
Principal Amount of this
2025 Fixed
Rate Global Note
	  	 Amount of increase in
Principal Amount of this
2025 Fixed
Rate Global Note
	  	 Principal Amount of this
2025 Fixed Rate Global
Note
following such
decrease or increase
	  	 Signature of authorized
signatory of Trustee
or
Registrar

  
 11EX-4.6

 Exhibit 4.6 

FORM OF 2027 FIXED RATE GLOBAL NOTE 

[FACE OF 2027 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.375% Fixed Rate Senior Note due 2027 

Guaranteed on a Senior Basis by 

Haleon plc 
 CUSIP No.:
36264F AK7 
 ISIN: US36264FAK75 
  

			
		 	 Principal Amount $
  

as revised by Schedule A
attached hereto of Increases and
Decreases in this 2027
Fixed Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the “Holder”)
of $                         of 3.375% Fixed Rate Senior Notes due 2027 represented by this Global Note. GSK
Consumer Healthcare Capital US LLC, a Delaware limited liability company, promises to pay to the Holder, or registered assigns, the principal sum of
$                             as revised by the Schedule of Increases and Decreases in 2027 Fixed Rate
Global Note attached hereto, on March 24, 2027. 
 In the event of a redemption or cancellation of the 2027 Fixed Rate Notes in part only, the 2027
Fixed Rate Notes evidenced by this 2027 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2027 Fixed Rate Notes represented by this 2027 Fixed Rate Global Note shall be the principal amount of
2027 Fixed Rate Notes most recently entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

 Reference is hereby made to the further provisions of this 2027 Fixed Rate Note as set forth on the reverse
hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC
		
	By:	 	
                     

		 	Name:
		 	Title:

 TRUSTEE’S CERTIFICATE OF 

AUTHENTICATION 
 Deutsche Bank Trust Company Americas, 

as Trustee, certifies 
 that this is one of 

the 2027 Fixed Rate Notes referred 
 to in the Indenture 

 

											
	By:	 	  
	 	                        	  	Date:	 	
                     
    
	  	                            
		 	Authorized Signatory	 		  		 		  	

  
 2 

 GUARANTEE 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY, England (the “Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Guarantee is endorsed and to the Trustee on behalf of each such Holder the due payment of all principal of and other amounts on, each Note payable by
GSK Consumer Healthcare Capital US LLC, a Delaware limited liability company (the “U.S. Issuer”, which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer, to
punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, the Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due,
payable or otherwise deliverable, whether on the stated maturity date or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 

The indebtedness evidenced by this Guarantee constitutes an unsubordinated and unsecured obligation of the Guarantor and ranks equally and
pari passu with all existing and future senior and unsecured obligations of the Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the
Guarantor. 
 The Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Guarantor hereby waives diligence, presentment, demand
of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness evidenced thereby or with
respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional Amounts, if
any, payable in respect of such Note. This Guarantee is a guarantee of payment and not of collection. 
 The Guarantor shall be subrogated
to all rights of the Holder of such Note and the Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Guarantor pursuant to the provisions of this Guarantee; provided, however, that the Guarantor shall not be
entitled to enforce, or to receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been
paid in full. 

  
 3 

 No reference herein to such Indenture and no provision of such Indenture shall alter or
impair the guarantees of the Guarantor, which are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Guarantee is endorsed. 

This Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been manually
or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Guarantee that are defined in such
Indenture shall have the meanings assigned to them in such Indenture. 
 This Guarantee shall be governed by and construed in accordance
with the laws of the State of New York. 

  
 4 

 IN WITNESS WHEREOF, the Guarantor has caused this Guarantee to be duly executed
this                    . 
  

			
	HALEON PLC,
	as the Guarantor
		
	By:	 	              

		 	Name:
		 	Title:
		
	By:	 	
                 

		 	Name:
		 	Title:

  
 5 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.375% Fixed Rate Senior Note due 2027 

Guaranteed on a Senior Basis by 

Haleon plc 
  

	1.	 Interest 

Interest on the 2027 Fixed Rate Notes will be payable at a rate of 3.375% per annum. 

Interest on the 2027 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing on
March 24, 2023 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2027 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed Rate
Notes Interest Payment Date. 
 The 2027 Fixed Rate Notes will accrue interest from (and including) September 24, 2022, or from the most recent Fixed
Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2027 Fixed Rate Notes will be paid on the basis of twelve 30-day months assuming
a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2027 Fixed Rate Notes and on the 2027 Fixed Rate Notes Maturity
Date, GSK Consumer Healthcare Capital US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of payments of any
other amounts or the Maturity Date, as the case may be. Holders must surrender 2027 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2027 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the transfer of immediately
available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by the payee by giving
written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its discretion). 

 

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent, calculation
agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the Guarantor may act as
Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 

  
 6 

	4.	 Indenture 

The Issuer issued the 2027 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from time to time in
accordance with the terms thereof, the “Indenture”), among the Issuers, GSK plc, the Guarantor, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2027 Fixed Rate Notes include those
stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2027 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a statement of
those terms. Each Holder by accepting a 2027 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2027 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                     aggregate principal amount. 

The 2027 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Guarantor under the Guarantee, for the benefit of the Holders pursuant to the
Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal amount on
March 24, 2027. 
  

	 	5.1	 Optional Redemption for Tax Reasons  

The Issuer may redeem the 2027 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of their principal
amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any change in or amendment to the laws
or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in the application or official
interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue Date: (i) the Issuer would
be required to pay Additional Amounts on the 2027 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available to the Issuer or the Guarantor;
or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the Guarantor (or any Affiliate) and such withholding tax obligation cannot be avoided by
the use of reasonable measures available to the Issuer or the Guarantor (or any Affiliate); or 
 (b) the Issuer determines, based upon an opinion of
independent counsel of recognised standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is
taken or brought on after the Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the
earliest date on which the Issuer would be obligated to pay such Additional Amounts. 

  
 7 

	 	5.2	 Make-Whole and Par Redemption 

Prior to the 2027 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2027 Fixed Rate Notes, in whole or in part, at its option at any time and from time
to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2027 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the present values of the remaining
scheduled payments of principal of and interest on the 2027 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that would be due if the 2027 Fixed Rate
Notes matured on the 2027 Fixed Rate Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day
months) at the Treasury Rate plus 20 basis points, in each case plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

On or after the 2027 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2027 Fixed Rate Notes, in whole or in part, at its option at any time and from
time to time at a redemption price equal to 100% of the principal amount of the 2027 Fixed Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

 

	 	5.3	 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the 2027 Fixed Rate Notes, the Holders will have the option to require the Issuer to redeem or, at the
Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2027 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control Redemption Amount
together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
  

	6.	 Denominations; Transfer 

The 2027 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A Holder may transfer
2027 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted by the Indenture.

  

	7.	 Persons Deemed Owners 

The registered Holder of this 2027 Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other amounts on, any
2027 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to the Issuer or (if
then held by the Issuer) shall be discharged from such trust. The Holder of such 2027 Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such amount must be
remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

  
 8 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2027 Fixed Rate Notes or the Guarantee may be amended with the consent of
the Holders of a majority in principal amount of the 2027 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in aggregate principal amount
of the 2027 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any Holder, the Issuer and the
Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide for the acceptance of
appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2027 Fixed Rate Notes in addition to or in place of certificated 2027 Fixed Rate Notes.

  

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the 2027 Fixed Rate Notes shall occur, the principal amount of all the 2027 Fixed Rate Notes may be declared to
become immediately due and payable. 
 Holders may not enforce the Indenture or the 2027 Fixed Rate Notes except as provided in the Indenture. The Trustee
may refuse to enforce the Indenture or the 2027 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become the owner or
pledgee of 2027 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not Trustee. 

 

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2027 Fixed Rate Notes or for any claim based thereon or otherwise in respect
thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the Guarantor in this Indenture, or in any of the 2027 Fixed Rate Notes, or because of the creation of any indebtedness represented thereby, shall be had
against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the Guarantor) or the Guarantor or of any successor Persons thereof. Each Holder, by accepting the 2027 Fixed Rate
Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2027 Fixed Rate Notes. Such waiver may not be effective to waive liabilities under U.S. federal securities laws. 

  
 9 

	13.	 Authentication 

This 2027 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf) manually or
electronically signs the certificate of authentication on the other side of this 2027 Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the 2027 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to the accuracy of
such numbers either as printed on the 2027 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2027 Fixed Rate Notes. The Issuer will promptly notify the Trustee, in
writing, of any change in the “CUSIP” number. 
  

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and the Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising out of or based
upon the Indenture or the 2027 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and the Guarantor have irrevocably submitted to the non-exclusive
jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such proceeding, and any claim they may now or hereafter
have that any proceeding in any such court is brought in an inconvenient forum. The Guarantor has appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may be served in any suit, action or proceeding arising out of
or based upon the Indenture or the 2027 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the Issuer and the Guarantor have or hereafter may acquire any immunity
(sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process (whether service or notice, attachment in aid or otherwise) with respect
to themselves or any of their property, the Issuer and the Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of their obligations under the Indenture or the 2027 Fixed Rate Notes. 

The Issuer shall furnish to any Holder upon written request and without charge to the Holder a copy of the Indenture which has in it the text of this 2027
Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Mike Rowe (Group Treasurer), email address: cf-treasury@haleon.com, with copy to: Gregory Tole (VP and Secretary)
and Arlene Cannon (Assistant Secretary), email address: US.CorpSec@haleon.com. 

  
 10 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2027 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2027 Fixed Rate Global Note have been made: 

 

									
	 Date of Exchange
	  	 Amount of decrease
in Principal Amount
of this 2027
Fixed
Rate Global Note
	  	 Amount of increase
in Principal Amount
of this 2027
Fixed
Rate Global Note
	  	 Principal Amount of
this 2027 Fixed Rate
Global
Note
following such
decrease or increase
	  	 Signature of
authorized signatory
of Trustee
or
Registrar

		  		  		  		  	

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]